Abattis Bioceuticals Corp (OTCMKTS:ATTBF) is trending upward today after some volatility over the last month. ATTBF has rebalanced after their huge surge around mid-December to late January and many analysts are wondering if the stock can climb back over the $0.30 mark.

Recent news is positive and presents a nice catalyst for ATTBF and the market has also reacted favorably – as mentioned above. The most recent news announced that the company strengthened their partnership with dicentra. The latter is a consulting firm and looks to help ATTBF improve their push into the cannabis food and beverage division.

“Bringing dicentra’s experience and expertise to Abattis will help us to secure world-class regulatory and compliance services for Abattis and our clients and partners”, stated Rob Abenante, President and CEO of Abattis. “The Partnership will support our commitment to develop and manufacture food and beverages, cosmetics, pet products and over-the-counter health supplements containing cannabinoids that are compliant with current and future regulations in Canada and the United States”, added Mr. Abenante.

Abattis Bioceuticals Corp (OTCMKTS:ATTBF) casts itself as a specialty biotechnology company with capabilities through its wholly owned subsidiaries of cultivating, licensing and marketing proprietary ingredients, bio-similar compounds, patented equipment and consulting services to medicinal marijuana markets in North America.

In essence, ATTBF develops, licenses, and markets health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets in Canada. It is also involved in the possession of cannabis and related active ingredients, as well as the production of extracts; and bioceutical marketing services in the area of health products.

ATTBF was formerly known as Abattis Biologix Corporation and changed its name to Abattis Bioceuticals Corp. in September 2012. Abattis Bioceuticals Corp. was incorporated 1997 and is headquartered in Langley, Canada.

According to company materials, “Abattis is a life sciences and biotechnology company which aggregates, integrates, and invests in cannabis technologies and biotechnology services for the legal cannabis industry developing in Canada. The Company has successfully developed and licensed natural health products, medicines, extractions, and ingredients for the biologics, nutraceutical, bioceutical, and cosmetic markets. The Company is also seeking to acquire exclusive intellectual property rights to agricultural technologies to be employed in extraction and processing of botanical ingredients and compounds. The Company follows strict standard operating protocols, and adheres to the applicable laws of Canada and foreign jurisdictions.”

Find out when $ATTBF reaches critical levels. Subscribe to FinanceRegistrar.com Right Now by entering your Email in the box below.

In other news, ATTBF also signed an LOI with Canadian Artesian to develop and manufacture a CBDp-infused beverage. Canadian Artesian makes Clearly Canadian and could be a nice partnership for ATTBF.

“We are very excited about our new partnership with Canadian Artesian.” stated Rob Abenante, President and CEO of Abattis. “The bottled water market is expected to be approximately $280 billion by 2020* and we believe point of origin will be the key differentiator among big players. In light of recent research indicating that more than 60% of North American bottled water comes from municipal water sources, Canadian Artesian’s access to premium mineral well water positions it to produce a world-class line of CBD-infused mineral waters.”

Currently trading at a market capitalization of $80.68M, ATTBF is pre-revenue at this point but does have a few nice partnerships to get its feet wet in this burgeoning industry. ATTBF should be on your radar because of the size of this market and their potential. We will update the story again soon as further details emerge. Sign-up for continuing coverage on shares of $ATTBF stock, as well as other hot stock picks, get our free newsletter today and get our next breakout pick!

Disclosure: we hold no position in $ATTBF, either long or short, and we have not been compensated for this article.